Progressive study of effects of erianin on anticancer activity

Yuying Zhang1, Qianqian Zhang1, Fanhua Wei2, Na Liu1

1School of Biological Science and Technology, University of Jinan, Jinan 250022, People’s Republic of China; 2College of Agriculture, Ningxia University, Yinchuan 750021, People’s Republic of China

Abstract: Erianin is the major bisbenzyl compound extracted from the traditional Chinese medicine Dendrobium chrysotoxum Lindl. Erianin possesses many biological properties relevant to cancer prevention and therapy. The previous studies confirmed that antitumor effects of erianin are regulated with multiple signaling pathways. The mechanisms of erianin are numerous, and most of them induce cancer cell apoptosis that may be intrinsic or extrinsic and modulate the ROS/JNK signaling pathways. Invasion, migration, and angiogenesis represent emerging targets of erianin and support its anticancer properties. This review aimed to summarize the recent advances in the antitumor activity of erianin and to provide a rationale for further exploring the potential application of erianin in overcoming cancer in the future.

Keywords: Erianin, antitumor, apoptosis, cell cycle arrest, molecular mechanism

Introduction

Cancer is a critical illness whose cell division and growth are uncontrolled after gene mutation. It has been estimated that around 13.2 million cancer patients will die annually by 2030 worldwide.1 There are 14 million new cases and this number is expected to increase up to 22 million within the next two decades according to the statistical data from the WHO in 2012.2 The incidence of cancer is increasing because of the growth and aging of human population as well as because of an increasing prevalence of established risk factors such as obesity, smoking, physical inactivity, and changing reproductive patterns associated with economic development.3 The resistance of malignant cells to cancer therapeutics is the top reason for cancer treatment failure and makes cancer malignancies refractory and challenging.4,5 In addition, side effects and high costs of cancer therapies limit their clinical applications.6,7 Therefore, the development of novel anticancer drugs or therapeutics without side effects or in combination with chemotherapeutic agents is helpful for cancer therapy. Nowadays, natural products have attracted more attention because of their multi-target characteristics and their ability to bind to specific cellular targets.8

Medicinal plants are important sources of novel therapeutic drugs that are promising for cancer treatment.9 A number of bioactive constituents from Dendrobium plants, such as polysaccharides,10 bibenzyls,11 phenanthrones,12 alkaloids,13 sesquiterpenoids,14 fluorenone,15 coumarins,16 triterpene glycosides,17 and volatile oil chemical composition, are obtained and show diverse pharmacological functions including anticancer, neuroprotective, antidiabetic, and immune-modulating activities. Erianin, which is a natural
In recent years, several studies have shown in vitro and in vivo anticancer activities and anti-inflammation properties for erianin as a novel cancer therapeutic remedies in both preventing and overcoming cancer. This review summarizes the progress of erianin as a model of natural product in anticancer effects in recent years and expounds the molecular mechanism related to anticancer activity. Finally, we will provide future perspectives for erianin as a novel cancer therapeutic remedies in both preventing and overcoming cancer.

Structure and bioactivities of erianin

Erianin (2-methoxy-5-[[2-(3,4,5-trimethoxy-phe-nyl)-ethyl] -phenol] is a low-molecular-weight natural product which is first isolated from the Erionia coronaria of Orchidaceae in India and is also extracted from Dendrobium chrysotoxum Lindl. The erianin structure consists of two substituted aromatic (aryl) rings linked by a two-carbon alkene bridge with several methoxyl substitutions on the phenyl rings (Figure 1) and belongs to the bibenzyl derivatives. Many compounds of the bibenzyl derivatives have shown antiviral, antibacterial, and anti-inflammatory response and anticancer activities.

At present, multiple pharmacological effects of erianin have been elucidated, including antioxidative and antitumor activity. It is worth mentioning that erianin shows therapeutic potential to inhibit multiple cancers in vivo and in vitro. Erianin has been reported to inhibit cell proliferation and induce apoptosis in human osteosarcoma cells and reverse multidrug resistance in B16/hMDR-1 cells. Erianin treatment inhibits tumor growth in mice with HePA (tumor suppressor rate: 50.82%) and ESC (tumor suppressor rate: 51.96%). In addition, some stilbene and phenanthrene derivatives that have a structure similar to erianin, also display potent antitumor activity. For instance, combretastatin A-4 (CA-4), isolated from a South African tree Combretum caffrum, is one of the most naturally potent antitumor agent with activity in the low-nanomolar range. Previous research showed that CA-4 inhibits tubulin polymerization at the colchicine-binding site of β-tubulin and leads to cytoskeletal instability, resulting in morphological changes of immature or proliferating endothelial cells. Moreover, disodium phosphate CA-4P is undergoing several advanced clinical trials.

Despite remarkable anticancer properties of erianin, its application in pharmaceutical industries is limited for a variety of reasons, including low bioavailability, water solubility, and chemical stability; indeed, this molecule is rapidly and extensively decomposed and excreted. To overcome these, various attempts by medicinal chemistry have been made to improve the bioavailability of erianin. A previous study reported that the 1,1-ethane bridge encountered in isoeieranin derivatives can replace the 1,2-ethane bridge of natural erianin with no loss of activity. Several compounds exhibited excellent antiproliferative activity at nanomolar concentrations against a panel of human cancer cell lines. Next, research have demonstrated a new class of isoeieranin derivatives, named azaisoerianins, in which the two aromatic rings are connected through a nitrogen atom in place of the carbon linker in isoeieranin compounds. Azaisoerianins showed excellent antiproliferative activity with mean GI50 values at a nanomolar level in a diverse set of human cancer cells. These compounds also inhibited tubulin assembly at a micromolar range, arrested the cellular cycle in the G2/M phase, and induced apoptosis at very low

<table>
<thead>
<tr>
<th>Tumor cell types</th>
<th>IC50 (nmol/L)</th>
<th>Time (hr)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>K562 cell</td>
<td>14.13</td>
<td>72</td>
<td>[43]</td>
</tr>
<tr>
<td>HL-60 cell</td>
<td>38.00</td>
<td>24</td>
<td>[21]</td>
</tr>
<tr>
<td>I43B cell</td>
<td>40.97</td>
<td>48</td>
<td>[22]</td>
</tr>
<tr>
<td>MG63.2 cell</td>
<td>44.26</td>
<td>48</td>
<td>[22]</td>
</tr>
<tr>
<td>T47D cell</td>
<td>68.4</td>
<td>72</td>
<td>[19]</td>
</tr>
<tr>
<td>EJ cell</td>
<td>65.04</td>
<td>48</td>
<td>[44]</td>
</tr>
<tr>
<td>SGC-7901 cell</td>
<td>175.9</td>
<td>48</td>
<td>[45]</td>
</tr>
<tr>
<td>MGC803 cell</td>
<td>95.99</td>
<td>48</td>
<td>[46]</td>
</tr>
<tr>
<td>Huh7 cell</td>
<td>37.4</td>
<td>48</td>
<td>[47]</td>
</tr>
<tr>
<td>SW480 cell</td>
<td>24.5</td>
<td>48</td>
<td>[48]</td>
</tr>
<tr>
<td>Caco-2 cell</td>
<td>2654.19</td>
<td>48</td>
<td>[49]</td>
</tr>
<tr>
<td>HeLa cell</td>
<td>8300</td>
<td>48</td>
<td>[50]</td>
</tr>
</tbody>
</table>

![Figure 1](https://www.dovepress.com/10.2147/ott.d190548.g1) The chemical structure of erianin.
concentrations. Therefore, new formulations were designed and synthesized as a novel class of erianin analogs may be a way to improve erianin’s bioavailability and its druggability.

**Anticancer bioactivities and mechanisms of erianin**

**Apoptosis**

Apoptosis plays an important role in cancer treatment as most anticancer therapies primarily act by activating the apoptosis pathways, which are the final goals of anticancer therapies. There are two types of apoptosis pathways. One is the intrinsic pathway that occurs through mitochondrial pathway, which increases mitochondrial permeability, mitochondrial release of cytochrome C, and subsequent cysteiny1 aspartate-specific proteinase (caspase) activations. Caspase is a kind of protease family, which is divided into three categories, apoptosis initiation factors, apoptosis effect factors, and inflammatory mediators. Apoptosis initiation factors initiate programmed apoptosis, including caspase-2, caspase-8, caspase-9, caspase-10, and so on, which are cleaved by other proteins for activation of downstream caspases. For example, almost all caspases cascade reaction can be activated by caspase-8 to induce apoptosis. Apoptosis effect factors are located downstream of caspase cascade reaction, including caspase-3, caspase-6, and caspase-7, which act on their specific substrates. Caspase-3 is one of the most important apoptosis executors in the caspase family and is the main effector factor in apoptosis. In normal cells, caspase exists in an inactive zymogen form, but it is activated when cells are stimulated by apoptosis induction factors such as physical or chemical regulators. Extrinsic pathway involves activation of death receptors by ligand binding leading to the formation of the death-inducing signaling complex and activation of caspase-8, and final induction of the mitochondrial pathway.

The elevating evidence suggest that targeting apoptosis of cancer cells is feasible. Several proapoptotic and antiapoptotic proteins are attractive targets for anticancer therapies. Antiapoptotic proteins inhibit cancer cell apoptosis such as Bcl-2, Bcl-XL, Bcl-W, Mcl-1, Bfl1/A1, Bcl-G, and so on. The proapoptotic signal promotes cancer cell apoptosis including Bax, Bak, Bad, Bim, Bik, Puma, Noxa, and so on. Erianin can induce the early apoptosis and late apoptosis in T47D human breast cancer cells, and the proapoptotic effect of erianin depends on reducing Bcl-2 expression and activating caspase signaling. Erianin decreases human osteosarcoma cells viability in a time- and dose-dependent manner. HL-60 cells exposed to erianin of 12.5–81.9 nM/L show evident antiproliferative effect after 24, 48, and 72 hrs in a concentration-dependent manner, and erianin treatment induces cancer cell apoptosis by downregulating the expression of Bcl-2 gene while upregulating the expression of Bax gene. In EJ bladder cancer cells, erianin significantly inhibits cell proliferation in a dose-dependent manner, and the IC50 value is 65.04 nM/L after 48 hrs of exposure to erianin. Meanwhile, erianin-mediated inhibitory effect on proliferation of EJ cells is largely attenuated through the knockdown of Bim gene or over-expression of Bcl-2 gene. In gastric cancer SGC-7901 cells, erianin inhibits cell proliferation, and the IC50 value is 175.9 nM/L after treatment with erianin for 48 hrs, which probably depends on inhibition of telomerase activity. Furthermore, the effects of apoptosis by erianin in combination with 5-fluorouracil are more remarkable than alone by regulating the expressions of Bax, caspase-3, and Bcl-2.

The proapoptotic proteins in the Bcl-2 family normally act on the mitochondrial membrane to promote permeabilization and release of cytochrome C and reactive oxygen species (ROS), which are important signals in the apoptosis cascade. Basic levels of ROS may function as signals to promote cell proliferation and survival, whereas high levels of ROS can damage cellular components such as DNA, protein, and lipids. Hence, ROS plays a crucial role in cancer cell apoptosis and autophagy, which activates the JNK/c-jun signal pathway. Erianin induces an increase in ROS production, while pretreatment with ROS inhibitor NAC remarkably reverses erianin-induced inhibition of cell proliferation, apoptosis and autophagy in osteosarcoma cells. Erianin induces apoptosis and autophagy in human osteosarcoma cell lines by activating ROS-dependent JNK/c-jun pathway. Osteosarcoma cells treated with erianin leads to activation of JNK and c-Jun in a concentration-dependent manner, whereas when co-treated with JNK inhibitor sp600125 or dominant negative mutant of c-Jun, it markedly blocks erianin-induced growth-inhibitory and apoptotic effects, suggesting that JNK activation is required for the modulation of erianin-induced cancer cell apoptosis and autophagy. Furthermore, the JNK/stress-activated protein kinase (SAPK) signal is also involved in erianin-induced decreasing in acidification rate. JNK/SAPK inhibition can effectively abolish erianin-induced decreasing in ATP levels, and the effect on
endothelial metabolism is JNK/SAPK-dependent. JNK/SAPK activation is closely related with mitochondrial permeability, which plays a crucial role in cancer cell apoptosis. Exploring the mechanism involved in directly or indirectly regulating mitochondrial respiration is helpful for understanding the antitumor and antiangiogenic actions of erianin. Meanwhile, erianin-induced mitochondrial-based cancer cell apoptosis through the inhibition of ERK1/2 (extracellular signal-regulated kinase, ERK) signaling and the activation of p53 is also examined.

Caspase signaling plays an important role in the initiation and process of cell apoptosis. Caspase-3 is the main effector in cell apoptosis, which is activated in apoptotic cells both by extrinsic and by intrinsic pathways. In bladder cancer cells, erianin activates caspase cascade reaction and finally triggers the breakage of poly (ADP-ribose) polymerase (PARP) by many caspases in vitro and by caspase-3 in vivo and results in the PARP carboxy-terminal catalytic domain (89 kD) separated from the amino-terminal DNA-binding domain (24 kD), so that PARP abolishes its enzymatic activity and cannot be combined with other proteins to repair damaged DNA. In erianin-treated tumor tissues, erianin increases cleaved caspase-3 level and in apoptosis proportion by the TUNEL assay. In breast cancer cells, erianin treatment significantly upregulates the expression of cleaved caspase-3, caspase-7, and caspase-9 and alters the ratio of Bcl-2/Bax. In conclusion, erianin can induce tumor cell apoptosis as shown in Figure 2.

**Cell cycle**

Dysregulation of cell cycle checkpoint is an initiating event in cancer development allowing for cancer cell growth due to changes in intracellular signaling pathways that cause cells to enter the cell cycle without external stimuli. The growth factors bind to receptors on the cell membrane, resulting in signals transmitted through the membrane into the cytoplasm led to the activation of downstream target genes which stimulate cells to enter the cell cycle. Erianin has been found to arrest cell cycle at G2/M phase in a variety of cancer cells (except sgc-7091 cell S phase of gastric cancer and caco-2 cell G2 phase of colon cancer). Erianin treatment significantly increases amounts of cells at G2/M phase in a concentration-dependent and time-dependent manner in T47D cells and in HL-60 cells. In human osteosarcoma cells, erianin treatment increases cell number at G2/M phase after 24 hrs of treatment with elevating concentration, accompanied by decreased cell numbers at S and G0/G1 phases in 143B and MG63.2 cells. However, the molecular mechanisms involved in cell cycle arresting by erianin remain not very clear, although the modulation of multiple cell cycle regulatory proteins seems to be involved. Erianin treatment significantly upregulates the expression of p53, cyclin B1, p21, and p27, but significantly downregulates the mRNA levels of CDK1 and CDK7. It illustrates that erianin can upregulate the expression of p21, p27, and other genes to inhibit the activation of cyclin-CDK complexes and to cause G2/M phase arrest, as shown in Figure 3.

**Metastasis**

Cancer therapy is easy to relapse mainly due to a cancer diagnosis in later stages and when metastasis has occurred. The migration consists of three processes, including chemotactic migration of tumor cells, guidance of cell membrane elongation activity, between cells and their extracellular matrix adhesion ability, and protease hydrolysis. Therefore, how to effectively using its regulation process to inhibit the invasion and migration of tumor cells is also an urgent topic in anticancer strategies. Matrix
metalloproteinases (MMPs) play a crucial role in tumor metastasis. MMPs regulate extracellular matrix degradation and cell adhesion processes to enhance tumor cell invasion and metastasis. Among them, MMP-2 and MMP-9 are key regulators of tumor migration and are capable of degrading type IV collagen which is the most abundant component of the basement membrane. In tumor cells, MMPs are mainly regulated by MAPK (mitogen-activated protein kinases, MAPKs)/ERK signaling pathways and the expression of tissue inhibitor of matrix metalloproteinases (TIMPs).

Erianin treatment inhibits the migration of T47D cells by decreasing expression of ERα, p-ERK1/2, MMP2, and MMP9 and increasing expression of TIMP1 and TIMP2. In addition, erianin treatment leads to extensive tumor necrosis, growth delay, and rapid vascular shutdown in xenografted human hepatoma Bel7402 and melanoma A375 tumors by inducing endothelial cytoskeletal disorganization. Furthermore, erianin also inhibits the movement of tumor cells by upregulating the expression of E-cadherin and downregulating the expression of N-cadherin and fibronectin.

Overall, these results suggest that the migration of tumor cells is largely inhibited by erianin, which further acts on JAK2/STAT3 and ERK1/2 pathway and its downstream gene MMP-2 and MMP-9 to inhibit the tumor metastasis, as shown in Figure 4.

**Angiogenesis**

Tumor angiogenesis is the growth of new blood vessels around the tumor tissue to meet the needs of oxygen and nutrients for tumor cells. Indoleamine 2, 3-dioxygenase (IDO) is a rate-limiting enzyme of tryptophan metabolism along the kynurenine pathway. IDO can promote tumor cell invasion, metastasis, vasculogenic mimicry, and angiogenesis. Several inflammatory factors are involved in IDO regulation and angiogenesis such as COX-2, hypoxia-inducible factor 1 (HIF-1), IL-6, and so on. Furthermore, JAK (Janus kinase, JAK)/STAT (signal transducers and activators of transcription, STAT) pathway is closely related with IDO in tumor angiogenesis. Erianin effectively inhibits the expression of IDO and its enzyme.
activity in mice Lewis lung cancer 2LL cells. And erianin effectively decreases the expression of IDO-mediated inflammatory factors COX-2, HIF-1α, and IL-6. Meanwhile, erianin treatment decreases the phosphorylation of JAK2 and STAT3 levels and the expression of MMP2 and MMP9. As shown in Figure 5, erianin regulates the expression of key molecules in tumor angiogenesis and inflammatory microenvironment. Furthermore, erianin exhibits potent antiangiogenic activities in vitro by abrogating spontaneous or basic fibroblast growth factor-induced neovascularization, disrupting endothelial tube formation, inhibiting proliferation of human umbilical vein endothelial cells, and abolishing migration across collagen and adhesion to fibronectin. Erianin also induces endothelial cytoskeletal disorganization by depolymerizing both F-actin and β-tubulin. In addition, erianin inhibits HG-induced vascular endothelial growth factor (VEGF) expression, HIF-1α translocation into nucleus, and ERK1/2 activation in choroid-retinal endothelial cells RF/6A and microglia cells BV-2. In RF/6A cells, erianin inhibits VEGF-induced activation of VEGF receptor 2 and its downstream signaling pathways such as cRaf-MEK1/2-ERK1/2 and PI3K-AKT. Interestingly, ZJU-6, a derivative of erianin, has a significant antiangiogenesis capability to pancreatic cancer cells MiaPaCa-2, breast cancer cells MDA-468, and colon cancer cell line HCC-2998. The erianin derivative and its glycoside analog both have a potent inhibitory effect on HL-60 and lung cancer cells A549.

**Autophagy**

Dysregulated autophagy in cancer is reported in 1999. Autophagy causes a specific form of programmed cell death that is different from caspase-mediated apoptosis, which is characterized by the presence of autophagosomes in the cytoplasm and the lysosome degrades its contents. Autophagy, which is regarded as a promising strategy for enhancing the antitumor efficacy of chemotherapy drugs, has been under extensive investigation. Erianin treatment increases the number of autophagic vesicles and enhanced conversion of LC3B-I to LC3B-II. However, inhibition of autophagy by treatment with 3-MA increases erianin-induced cancer cell apoptosis, indicating that erianin-induced autophagy contributes to the cancer cell survival. In addition, growing evidence demonstrates that activation of the JNK pathway transduces oxidative stress signal to promote cell apoptosis and autophagy in response to various stress signals. Treatment with erianin induced a significant increase in JNK and c-Jun phosphorylation. The use of the JNK inhibitor or JNK activation is associated with the regulation of erianin-induced apoptosis and autophagy. Furthermore, ROS accumulation is involved in the activation of JNK/c-Jun pathway. Together, these data showed that erianin induced autophagy through activation of ROS-dependent JNK/c-Jun pathway, as shown in Figure 6. The role of autophagy in tumor suppression and progression is more complicated, since elevating evidence demonstrate a dual role of autophagy for therapeutic purposes in cancer. Therefore, it is necessary to future investigate the relationship between autophagy and apoptosis in erianin-mediated inhibition of tumor progression.

**Other mechanisms**

An inflammatory state is essential for promoting cancer progression and for achieving the full malignant phenotype. Thus, much effort need to be made to investigate whether erianin has a potential use in cancer immunotherapy, for example, enhancing innate immune cells activation, promoting the differentiation of monocytes into antigen-presenting cells, increasing the activation of IL-10 signaling, etc.
regulation mechanism will be helpful for conducting a molecular approach in finding the scientific basis of a natural product (Chinese characteristic and precious Chinese medicinal materials resources) in the future.

Acknowledgment
This work was financially supported by the National Natural Science Foundation of China (No. 31501104).

Disclosure
The authors report no conflicts of interest in this work.

References